A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

Adicet Bio is handing out pink slips to 30% of its staffers in tandem with a pipeline restructure that includes discontinuing ...

The company’s TYK2 inhibitor GLPG3667 sits on the chopping block as well. Galapagos is “actively exploring partnership ...

TCG Labs Soleil has secured $400 million to boost the firm’s ability to advance its biotech portfolio companies while also ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

The orthopedic implant maker Shoulder Innovations is the latest medtech to plan for a nine-figure IPO, as it looks to scale ...

Ikena and Inmagene have selected Kristin Yarema, Ph.D., to lead the company upon the anticipated closing of their merger.

Olympus has teamed up with Revival Healthcare Capital to launch a joint venture aimed at bringing robotics to ...

GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...

Chinese biotech company Leads Biolabs has hit the Hong Kong stock exchange, snagging $189 million through an initial public ...